FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150085505> ?p ?o ?g. }

• W2150085505 endingPage "1099" @default.
• W2150085505 startingPage "1090" @default.
• W2150085505 abstract "Background In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up. Methods We did a single-blind, all-comer superiority trial in adult patients with chronic stable coronary artery disease or acute coronary syndromes, and at least one target lesion. Patients were treated at one of five percutaneous coronary intervention centres between January, 2006, and August, 2007. Computer-generated block randomisation and a telephone allocation service were used to randomly assign patients to receive the zotarolimus-eluting or the sirolimus-eluting stent. Data for follow-up were obtained from national Danish administrative and health-care registries. The primary endpoint was a composite of major adverse cardiac events within 9 months: cardiac death, myocardial infarction, and target vessel revascularisation. Intention-to-treat analyses were done at 9-month and 18-month follow-up. This trial is registered with ClinicalTrials.gov, number NCT00660478. Findings 1162 patients (1619 lesions) were assigned to receive the zotarolimus-eluting stent, and 1170 patients (1611 lesions) to receive the sirolimus-eluting stent. 67 patients (72 lesions) had stent failure, and six patients were lost to follow-up. All randomly assigned patients were included in analyses at 9-month follow-up; 2200 patients (94%) had completed 18-month follow-up by the time of our assessment. At 9 months, the primary endpoint had occurred in a higher proportion of patients treated with the zotarolimus-eluting stent than in those treated with the sirolimus-eluting stent (72 [6%] vs 34 [3%]; HR 2·15, 95% CI 1·43–3·23; p=0·0002). At 18-month follow-up, this difference was sustained (113 [10%] vs 53 [5%]; 2·19, 1·58–3·04; p<0·0001). For patients receiving the zotarolimus-eluting stent and those receiving the sirolimus-eluting stent, all cause-mortality was similar at 9-month follow-up (25 [2%] vs 18 [2%]; 1·40, 0·76–2·56; p=0·28), but was significantly different at 18-month follow-up (51 [4%] vs 32 [3%]; 1·61, 1·03–2·50; p=0·035). Interpretation The sirolimus-eluting stent is superior to the zotarolimus-eluting stent for patients receiving routine clinical care. Funding Cordis and Medtronic." @default.
• W2150085505 created "2016-06-24" @default.
• W2150085505 creator A5002757728 @default.
• W2150085505 creator A5004368211 @default.
• W2150085505 creator A5005510617 @default.
• W2150085505 creator A5006148147 @default.
• W2150085505 creator A5008573347 @default.
• W2150085505 creator A5013878625 @default.
• W2150085505 creator A5016659797 @default.
• W2150085505 creator A5041318172 @default.
• W2150085505 creator A5043444396 @default.
• W2150085505 creator A5043566061 @default.
• W2150085505 creator A5043651342 @default.
• W2150085505 creator A5043732373 @default.
• W2150085505 creator A5050037180 @default.
• W2150085505 creator A5050103205 @default.
• W2150085505 creator A5055011899 @default.
• W2150085505 creator A5055579981 @default.
• W2150085505 creator A5057310232 @default.
• W2150085505 creator A5059617202 @default.
• W2150085505 creator A5060335933 @default.
• W2150085505 creator A5066577006 @default.
• W2150085505 creator A5068286823 @default.
• W2150085505 creator A5080676555 @default.
• W2150085505 creator A5080877318 @default.
• W2150085505 creator A5087487098 @default.
• W2150085505 date "2010-03-01" @default.
• W2150085505 modified "2023-10-16" @default.
• W2150085505 title "Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial" @default.
• W2150085505 cites W105018345 @default.
• W2150085505 cites W1220723225 @default.
• W2150085505 cites W149951570 @default.
• W2150085505 cites W1511423923 @default.
• W2150085505 cites W1572943973 @default.
• W2150085505 cites W1774610061 @default.
• W2150085505 cites W1982954035 @default.
• W2150085505 cites W1989556574 @default.
• W2150085505 cites W1991380668 @default.
• W2150085505 cites W2013952880 @default.
• W2150085505 cites W2022515531 @default.
• W2150085505 cites W2031498851 @default.
• W2150085505 cites W2055189890 @default.
• W2150085505 cites W2067233983 @default.
• W2150085505 cites W2077883810 @default.
• W2150085505 cites W2078761244 @default.
• W2150085505 cites W2082511254 @default.
• W2150085505 cites W2083630382 @default.
• W2150085505 cites W2087150869 @default.
• W2150085505 cites W2087815860 @default.
• W2150085505 cites W2105332661 @default.
• W2150085505 cites W2119470649 @default.
• W2150085505 cites W2120050284 @default.
• W2150085505 cites W2129811129 @default.
• W2150085505 cites W2146743728 @default.
• W2150085505 cites W2151857625 @default.
• W2150085505 cites W2157880649 @default.
• W2150085505 cites W2163231121 @default.
• W2150085505 cites W2171438563 @default.
• W2150085505 cites W2272962241 @default.
• W2150085505 cites W2613557783 @default.
• W2150085505 doi "https://doi.org/10.1016/s0140-6736(10)60208-5" @default.
• W2150085505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20231034" @default.
• W2150085505 hasPublicationYear "2010" @default.
• W2150085505 type Work @default.
• W2150085505 sameAs 2150085505 @default.
• W2150085505 citedByCount "197" @default.
• W2150085505 countsByYear W21500855052012 @default.
• W2150085505 countsByYear W21500855052013 @default.
• W2150085505 countsByYear W21500855052014 @default.
• W2150085505 countsByYear W21500855052015 @default.
• W2150085505 countsByYear W21500855052016 @default.
• W2150085505 countsByYear W21500855052017 @default.
• W2150085505 countsByYear W21500855052018 @default.
• W2150085505 countsByYear W21500855052019 @default.
• W2150085505 countsByYear W21500855052020 @default.
• W2150085505 countsByYear W21500855052021 @default.
• W2150085505 countsByYear W21500855052022 @default.
• W2150085505 countsByYear W21500855052023 @default.
• W2150085505 crossrefType "journal-article" @default.
• W2150085505 hasAuthorship W2150085505A5002757728 @default.
• W2150085505 hasAuthorship W2150085505A5004368211 @default.
• W2150085505 hasAuthorship W2150085505A5005510617 @default.
• W2150085505 hasAuthorship W2150085505A5006148147 @default.
• W2150085505 hasAuthorship W2150085505A5008573347 @default.
• W2150085505 hasAuthorship W2150085505A5013878625 @default.
• W2150085505 hasAuthorship W2150085505A5016659797 @default.
• W2150085505 hasAuthorship W2150085505A5041318172 @default.
• W2150085505 hasAuthorship W2150085505A5043444396 @default.
• W2150085505 hasAuthorship W2150085505A5043566061 @default.
• W2150085505 hasAuthorship W2150085505A5043651342 @default.
• W2150085505 hasAuthorship W2150085505A5043732373 @default.
• W2150085505 hasAuthorship W2150085505A5050037180 @default.
• W2150085505 hasAuthorship W2150085505A5050103205 @default.
• W2150085505 hasAuthorship W2150085505A5055011899 @default.
• W2150085505 hasAuthorship W2150085505A5055579981 @default.
• W2150085505 hasAuthorship W2150085505A5057310232 @default.
• W2150085505 hasAuthorship W2150085505A5059617202 @default.
• W2150085505 hasAuthorship W2150085505A5060335933 @default.

• next